Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.
Schol et al. describe in this perspective the key role of myeloid effector cells in tumor control during successful immunotherapy. They also discuss myeloid cell tumor-rejecting…
Discuss the importance of starting with pilot efforts to address challenges. Negotiate responsibilities across your team – reassess and reassign responsibilities based on expertise, availability,…
Recently, a team at the OSUCCC – James completed its first gene therapy for a patient with hemophilia B, the first at an adult medical…
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Resources to support hematologists with both continuing medical education and maintaining board certifications.
Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.
SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results…
Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.
SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.
